This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
STERIS (STE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Within Life Sciences, STERIS (STE) might have registered benefit from pharma customers on growing vaccines and biologics businesses in Q2.
Analysts Estimate Steris (STE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Steris (STE) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Steris (STE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
STERIS (STE) is optimistic about maintaining growth momentum on broader product and service portfolio along with strength in its Life Sciences business.
Steris (STE) Up 0.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
STERIS' (STE) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2021 results reflect strong performance by the Life Sciences segment despite the coronavirus-led economic crisis.
Steris (STE) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 35.05% and 4.55%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
STERIS (STE) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS (STE) registers declines in Healthcare Products with neutral performance in Life Science and AST in April, which is likely to have impacted Q1 earnings.
Analysts Estimate Steris (STE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STERIS (STE) Segmental Growth Robust Amid Coronavirus Woes
by Zacks Equity Research
As a major landmark for STERIS (STE), in fiscal 2020, the company joined the coveted S&P 500 Index.
STERIS' (STE) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
STERIS' (STE) fourth-quarter fiscal 2020 results reflect strong segmental performance despite the coronavirus-led economic crisis.
Steris (STE) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 4.46% and 4.39%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Roster for May 13: SDC, STE & More
by Urmimala Biswas
Many medical product companies register strong earnings growth in Q1, riding on huge market adoption of their COVID-19-related support products and growing demand for non-elective procedures.
Steris (STE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Steris (STE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add STERIS (STE) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about STERIS (STE) on its strong segmental growth in the third quarter of 2020.
5 Top S&P 500 Stocks That Rallied Last Week Defying Coronavirus
by Nalak Das
Despite coronovirus upsurge, a handful of S&P 500 stocks rallied last week. Some of them carry a favorable Zacks Rank with strong potential for future growth.
Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
The coronavirus outbreak had an immaterial impact on Walgreens Boots' (WBA) second-quarter fiscal 2020 results.
Bruker (BRKR) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Bruker's (BRKR) fourth-quarter 2019 results reflect strong performances by the majority of its segments and geographies.
STERIS' (STE) Organic Growth Robust Amid Bottom-Line Hurdles
by Zacks Equity Research
STERIS (STE) continues to register stellar organic growth across all four operating segments.
Neogen (NEOG) Q3 Earnings & Revenues Miss, Margins Decline
by Zacks Equity Research
Neogen's (NEOG) fiscal third-quarter 2020 results reflect strength in the Animal Safety segment.
Zacks.com featured highlights include: Medtronic, STERIS and Enova International
by Zacks Equity Research
Zacks.com featured highlights include: Medtronic, STERIS and Enova International
3 Top Stocks to Buy for Earnings Acceleration
by Tirthankar Chakraborty
Studies have shown that a majority of stocks had seen acceleration in earnings before a rally in stock price.
Steris (STE) Down 6.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
National Vision (EYE) Rides on Robust Growth Across All Lines
by Zacks Equity Research
National Vision (EYE) continues to register strong segmental performances.